Australia Health

Dimerix (ASX:DXB) has received feedback from the US Food and Drug Administration on its ACTION3 Phase 3 trial of DMX-200.

Paradigm Biopharmaceuticals (ASX:PAR) has confirmed that it has achieved approximately 25% of target recruitment in its pivotal Phase 3 PARA_OA_012 clinical trial.

Ramsay Health Care (ASX:RHC) has agreed to acquire the assets and operations of National Capital Private Hospital in Canberra.

CONNEǪT Health (ASX:CǪT) has secured $3.1 million (before costs) through a placement of new fully paid ordinary shares at $0.045 per share.

Reece (ASX:REH) has announced a $50 million increase to its on-market share buyback, lifting the total target to $85 million.

Health Canada has approved Neuren Pharmaceuticals' (ASX:NEU) clinical trial application for the Koala Phase 3 clinical trial.

Dimerix (ASX:DXB) confirmed that BioMarin Pharmaceutical (NASDAQ:BMRN) entered into a definitive agreement to acquire its US commercial licensing partner, Amicus Therapeutics (NASDAQ:FOLD)

Regis Healthcare (ASX:REG) announced that Dr Linda Mellors will resign as CEO and Managing Director after more than six years at the helm.

Memphasys (ASX:MEM) has signed a five-year commercial supply agreement with Centro Fertilita Assistita Italia, one of Italy's largest private IVF groups based in Naples.

Mayne Pharma Group (ASX:MYX) reported total net revenues of $165 million, a 5.5% decrease compared to the prior corresponding period.

Wesfarmers (ASX:WES) has placed more than 50 Priceline pharmacies operated by its largest franchisee, Infinity Pharmacy Group, into receivership.

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) has raised $5 million through a strongly supported placement.